Cannabidiol (CBD), one of 113 identified cannabanoids, has known anti-inflammatory and pain-relieving properties. In dermatology, a variety of topical products are becoming increasingly available to patients; however, much work remains to create CBD-containing dermatology products that can effectively treat skin disorders, one expert says.
“Currently, there aren’t many high-quality, high-standard CBD products on the market,” says Michael Milane, M.D., MBA, MPH, chief executive officer of Greenway Therapeutix, a company focused on developing novel dermatology therapeutics. “There’s a lot of hype out there, but it’s still the Wild West. For the most part, they don’t reach the standards we’re accustomed to in dermatology.”
To date, most CBD products haven’t provided much therapeutic effect, Dr. Milane says. In most instances, they don’t contain enough CBD to be significantly impactful. And, there’s no existing data identifying the best CBD concentration.
Additionally, CBD is most often included in oil solutions or emulsions, and the molecules respond exactly like oil when it touches water — it clumps up, making it impossible for CBD to penetrate the skin. Greenway Therapeutix is actively trying to solve this problem, he says.
“Barrier penetration is an issue,” he says. “We’ve put a lot of nanotechnology science into making CBD component penetration in these products a lot more feasible.”
So far, they’ve been successful in reducing the symptoms of atopic dermatitis and acne. Clinical testing is still underway, he says.
Dr. Milane is the president and CEO of Greenway Therapeutix which is dedicated to the research and development of medical grade cannabinoid therapeutic products using nanotechnology, Dr. Siegel is CSO and Chair, Scientific Advisory Board for Greenway Therapeutix.